+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID07770113

Evaluating Adebrelimab and Apatinib Mesylate with Albumin-bound Paclitaxel in Advanced Second-line Gastric and Gastroesophageal Junction Adenocarcinoma

Led by The First Affiliated Hospital of Zhengzhou University · Updated on 2026-08-18

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of combining adebrelimab with apatinib mesylate and albumin-bound paclitaxel, compared to apatinib mesylate with albumin-bound paclitaxel, in people with advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma who have not responded to first-line treatment. This randomized, open-label trial plans to enroll 50 participants and focuses on measuring the time until the cancer progresses or the patient passes away. Participants will be randomly assigned to one of two groups. The first group receives adebrelimab intravenously every 21 days, apatinib mesylate taken orally daily for 21 days, and albumin-bound paclitaxel intravenously once every 21 days for 4 to 6 cycles. The second group receives apatinib mesylate orally daily for 21 days and albumin-bound paclitaxel intravenously once every 21 days for 4 to 6 cycles. Treatment continues until disease progression, intolerable side effects, or for a maximum of two years for the oral and intravenous medications. During the study, participants undergo screening lasting up to 28 days to confirm eligibility. They will have regular assessments including tumor measurements every two treatment cycles, laboratory tests, heart and lung function tests, and monitoring for side effects at the end of each treatment cycle. The primary measurement is progression-free survival over up to 24 months. Secondary measures include overall survival, response rates, duration of response, and adverse events. Participants are monitored closely throughout treatment and follow-up until study completion.

CONDITIONS

Brief Title

A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer

Research Team

Y

Yongxu Jia Chief Physician

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here